Novo Nordisk, the Danish pharmaceutical company, has raised its full-year sales and operating profit outlook due to surging demand for its weight loss drug Wegovy and diabetes treatment Ozempic. The company now expects 2023 sales growth in local currencies of 32% to 38%, up from the previous outlook of 27% to 33%, and operating profit… Continue reading Novo Nordisk hikes outlook on soaring demand for Wegovy, Ozempic

Community health centers across the United States are facing delays in receiving updated Covid vaccines, hindering their ability to vaccinate vulnerable adults and children ahead of a potential winter wave. These centers, which provide federally funded free or low-cost health services, play a critical role in serving underserved populations, including those with low incomes, undocumented… Continue reading ‘Waiting with bated breath’: Health clinics anxious for Covid vaccines weeks after rollout

Walgreens reported fiscal fourth-quarter earnings that fell short of expectations as the demand for Covid vaccines and tests in the U.S. declined. The company has been facing challenges, including the transition out of the Covid pandemic, a leadership shake-up, and its push into healthcare. It also experienced labor pressure from pharmacy staff, some of whom… Continue reading Walgreens profit outlook comes up short as demand declines for Covid vaccines and tests

Agomab Therapeutics, based in Ghent, Belgium, has successfully raised approximately €94.9 million ($100 million) in a Series C funding round. Fidelity Management & Research Company led the round, with participation from new investors EQT Life Sciences, Canaan, Dawn Biopharma (controlled by KKR), and existing investors. The financing will support Agomab’s Phase 2a clinical trial, STENOVA,… Continue reading Belgian biotech company Agomab Therapeutics raises €94.9M to tackle fibrosis; here’s how 

Novo Nordisk has announced the early termination of a clinical trial for its diabetes drug Ozempic, designed to study its effectiveness in treating kidney failure in diabetes patients. The trial was stopped almost a year ahead of schedule based on a recommendation from the independent data monitoring board overseeing the study. Their decision was influenced… Continue reading Novo Nordisk stops Ozempic kidney trial after early signs of success

The Newfoundland and Labrador Health Authority has begun scheduling COVID and flu vaccine appointments, with clinics starting the following week. Starting on October 16, the province will distribute a COVID-19 vaccine specifically designed to target the Omicron XBB.1.5 variant to better match recent circulating coronavirus strains. Dr. Janice Fitzgerald, the province’s chief medical officer of… Continue reading Double dose: N.L. Health Services opening fall vaccinations for flu and COVID-19

Hound Labs, a California-based biotechnology company, has introduced a “marijuana breathalyzer” designed for employers to detect recent cannabis use in workers and discourage on-duty marijuana use. This development comes as New York enacted a law banning employers from testing workers for cannabis without signs of impairment when legalizing recreational marijuana. However, this law left both… Continue reading ‘Marijuana breathalyzer’ hopes to help workplace screening

AstronauTx, a UK biotech firm specializing in research on Alzheimer’s and other neurodegenerative diseases, has successfully raised £48 million (approximately $61 million) in its first major funding round. While the company doesn’t anticipate any of its drug candidates to reach clinical trials for at least three or four years, this financing marks a significant step… Continue reading UK biotech group raises £48mn for Alzheimer’s research

VitaDAO, a decentralized autonomous organization (DAO) focused on funding longevity research, is launching Matrix Biosciences, a biotech firm led by anti-aging researcher Vera Gorbunova from the University of Rochester. The company aims to expand on Gorbunova’s research on naked mole rats, known for their long lifespans and cancer resistance, to investigate whether a compound found… Continue reading Pfizer-backed VitaDAO spins out biotech company

Medexus Pharmaceuticals Inc. has closed its bought deal public offering of 3,389,900 units at a price of $2.95 per unit for aggregate gross proceeds to Medexus of $10,000,205. The net proceeds from the offering, after deducting underwriting discounts and commissions and offering expenses, will be used for working capital and general corporate purposes, which may… Continue reading MEDEXUS ANNOUNCES CLOSING OF C$10 MILLION BOUGHT-DEAL PUBLIC OFFERING

Shares of Dutch health technology company Philips experienced a significant drop, falling over 9% in London trading, following a statement from the U.S. Food and Drug Administration (FDA). The FDA expressed dissatisfaction with Philips’ handling of a major product recall involving millions of ventilators used to treat sleep apnea. The FDA stated that the testing… Continue reading Philips shares fall 9% after U.S. drug regulator deals fresh blow to sleep device recall

Awakn Life Sciences Corp. has completed a feasibility study for its proprietary formulation of MDMA (3,4-methylenedioxymethamphetamine) using Catalent’s Zydis orally disintegrating tablet (ODT) technology. The study, which was initiated in February, 2023, evaluated a variety of chemical parameters and several aspects of MDMA on Catalent’s Zydis ODT technology. The aims of the feasibility study were… Continue reading AWAKN LIFE SCIENCES COMPLETES MDMA ZYDIS(R) ODT FEASIBILITY STUDY